{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:56:30Z","timestamp":1790826990449,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.trre.2024.100837","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:11:24Z","timestamp":1708560684000},"page":"100837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Post-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type"],"prefix":"10.1016","volume":"38","author":[{"given":"Mehmet","family":"Ergisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Papalois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2024.100837_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ajt.14603","article-title":"Comprehensive review of post-organ transplant hematologic cancers","volume":"18","author":"Dharnidharka","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.trre.2024.100837_bb0015","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0020","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.trre.2024.100837_bb0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk","volume":"2","author":"Dharnidharka","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0030","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1600-6143.2011.03893.x","article-title":"Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States","volume":"12","author":"Dharnidharka","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0040","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfx356","article-title":"Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study","volume":"33","author":"Francis","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0045","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of Posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in U.S. Kidney Recipients","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trre.2024.100837_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0060","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.1998.16.6.2052","article-title":"Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?","volume":"16","author":"Leblond","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0065","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1345\/aph.1G706","article-title":"Posttransplant lymphoproliferative disorder","volume":"41","author":"Everly","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.trre.2024.100837_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1701554","article-title":"B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome","volume":"23","author":"Gross","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1399-0012.2005.00342.x","article-title":"Early onset post-transplant lymphoproliferative disease is associated with allograft localization","volume":"19","author":"Bakker","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-Transplant Lymphoproliferative Disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.trre.2024.100837_bb0085","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.transproceed.2021.04.020","article-title":"Heterogeneous manifestations of posttransplant lymphoma in renal transplant recipients: a case series","volume":"53","author":"Patil","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100837_bb0090","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/01.pas.0000213317.59176.d2","article-title":"Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study","volume":"30","author":"Johnson","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.trre.2024.100837_bb0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2215\/CJN.14570920","article-title":"De novo malignancies after kidney transplantation","volume":"17","author":"Al-Adra","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100837_bb0100","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids","volume":"8","author":"McDonald","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0105","unstructured":"Martinez O., Krams S., Robien M., Lapasaran M., Arvedson M., Weinberg K., Boyd S., Armstrong B., Twist C., Gratzinger D., Tan B., Trickey A., Sever M., Brown M., Bernstein D. EC. Gain of function mutation in latent membrane protein 1 of ebstein barr virus are associated with increased risk of post-transplant lymphoproliferative disorder. AJT [Internet]. 21. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/ajt.16847."},{"key":"10.1016\/j.trre.2024.100837_bb0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/0886022X.2020.1792927","article-title":"Does rabbit anti-thymocyte globulin dose and antiviral prophylaxis alter the risk of the development of PTLD in renal transplant population?","volume":"42","author":"Mohamed","year":"2020","journal-title":"Ren Fail"},{"key":"10.1016\/j.trre.2024.100837_bb0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/0886022X.2020.1759636","article-title":"Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population","volume":"42","author":"Ali","year":"2020","journal-title":"Ren Fail"},{"key":"10.1016\/j.trre.2024.100837_bb0120","unstructured":"Gruessner A., Saggi S., Renz J. Risk factors for the development of posttransplant lymphoproliferative disorder after pancreas transplantation \u2013 a registry analysis. AJT [Internet]. 21. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/ajt.16847."},{"key":"10.1016\/j.trre.2024.100837_bb0125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/tri.13624","article-title":"The Fc\u03b3RIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients \u2013 a retrospective study","volume":"33","author":"Gatault","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100837_bb0130","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/jcm9072193","article-title":"Impacts of high intra- and inter-individual variability in tacrolimus pharmacokinetics and fast tacrolimus metabolism on outcomes of solid organ transplant recipients","volume":"9","author":"Thongprayoon","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.trre.2024.100837_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.18632\/oncotarget.26522","article-title":"A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature","volume":"10","author":"Velvet","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.trre.2024.100837_bb0140","first-page":"1","article-title":"Immunosuppressive therapy for kidney transplant in adults","author":"National Institute for Health and Care Excellence","year":"2017","journal-title":"Technol Apprais Guid"},{"key":"10.1016\/j.trre.2024.100837_bb0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0150","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults With CD20-positive B Cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/10428190400012011","article-title":"Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era","volume":"46","author":"Ghobrial","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trre.2024.100837_bb0160","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","article-title":"Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders","volume":"19","author":"Leblond","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0165","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0170","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3324\/haematol.2023.283097","article-title":"The International Prognostic Index: still relevant 30 years later","volume":"108","author":"LaCasce","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.trre.2024.100837_bb0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.trre.2024.100837_bb0180","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0185","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0190","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trre.2024.100837_bb0195","article-title":"Single-institution retrospective analysis of prognostic factors influencing very late-onset post-transplant lymphoproliferative disorder","volume":"12","author":"Bishnoi","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.trre.2024.100837_bb0200","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/cncr.31339","article-title":"Impact of the posttransplant lymphoproliferative disorder subtype on survival","volume":"124","author":"Koff","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.trre.2024.100837_bb0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/13696998.2021.1915793","article-title":"Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status","volume":"24","author":"Hart","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.trre.2024.100837_bb0210","author":"American Society of Nephrology"},{"key":"10.1016\/j.trre.2024.100837_bb0215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/iju.14750","article-title":"Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: a real-world retrospective analysis in Japan","volume":"29","author":"Kato","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.trre.2024.100837_bb0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00467-019-04401-9","article-title":"Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients","volume":"35","author":"Ladfors","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2024.100837_bb0225","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2018-99-114686","article-title":"Risk of post-Transplant Lymphoproliferative Disorders (PTLD) in solid organ transplantation patients with EBV viremia","volume":"132","author":"Sawalha","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0230","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation infectious diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0235","article-title":"Clinical utility of epstein-barr virus viral load monitoring and risk factors for posttransplant lymphoproliferative disorders after kidney transplantation: a single-center, 10-year observational cohort study","volume":"3","author":"Franceschini","year":"2017","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2024.100837_bb0240","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.17421","article-title":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients \u2014 a British Society for Haematology guideline","volume":"193","author":"Shah","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trre.2024.100837_bb0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(\u2605)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0250","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1097\/TP.0000000000003183","article-title":"Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant","volume":"104","author":"Burns","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0255","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0260","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0265","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","article-title":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","volume":"36","author":"Zimmermann","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.trre.2024.100837_bb0270","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.3390\/curroncol28060426","article-title":"Durable response to Brentuximab Vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) in a patient with CD30-positive PTCL arising as a post-transplant lymphoproliferative disorder (PTLD)","volume":"28","author":"Hong","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0275","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/0284186X.2020.1731924","article-title":"CD30 expression and survival in posttransplant lymphoproliferative disorders","volume":"59","author":"Kinch","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0280","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0285","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100837_bb0290","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/TP.0000000000001099","article-title":"T cell PTLD successfully treated with single-agent Brentuximab Vedotin First-line therapy","volume":"100","author":"Choi","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0295","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/lt.23918","article-title":"First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis","volume":"20","author":"Schaefer","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2024.100837_bb0300","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fmed.2019.00295","article-title":"Refractory Epstein-Barr Virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes","volume":"6","author":"Mika","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.trre.2024.100837_bb0305","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1080\/10428194.2021.1957867","article-title":"A phase I\/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and\/or EBV + lymphomas","volume":"62","author":"Pearse","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trre.2024.100837_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.semnephrol.2022.01.003","article-title":"Emerging concepts in managing malignancy in kidney transplant patients","volume":"42","author":"Schreiber","year":"2022","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trre.2024.100837_bb0315","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2021.01.015","article-title":"Posttransplant lymphoproliferative disorder following kidney transplantation: a review","volume":"78","author":"Sprangers","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100837_bb0320","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trre.2024.100837_bb0330","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100837_bb0335","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trre.2024.100837_bb0340","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0345","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2021-149786","article-title":"Real World Evidence (RWE) of safety, efficacy, and outcomes of CD19 CAR-T therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0350","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41409-020-01145-1","article-title":"Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series","volume":"56","author":"Luttwak","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0355","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trre.2024.100837_bb0360","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/tri.14107","article-title":"EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review","volume":"34","author":"Liu","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100837_bb0365","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.trre.2024.100837_bb0370","first-page":"646","article-title":"Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment","volume":"4","author":"Shahid","year":"2021","journal-title":"Cancer Drug Resist (Alhambra, Calif)"},{"key":"10.1016\/j.trre.2024.100837_bb0375","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0380","doi-asserted-by":"crossref","first-page":"567020","DOI":"10.3389\/fimmu.2020.567020","article-title":"Management of PTLD after hematopoietic stem cell transplantation: immunological perspectives","volume":"11","author":"Compagno","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100837_bb0385","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trre.2024.100837_bb0390","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.transproceed.2004.12.130","article-title":"Posttransplant lymphoproliferative disorder: significance of central nervous system involvement","volume":"37","author":"Buell","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100837_bb0395","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","article-title":"CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation","volume":"25","author":"Maecker","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0400","doi-asserted-by":"crossref","first-page":"33849","DOI":"10.18632\/oncotarget.5292","article-title":"Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage","volume":"6","author":"Crane","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trre.2024.100837_bb0405","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1789.2010.01177.x","article-title":"A case of Epstein-Barr virus associated post-transplant lymphoproliferative disorder with CNS involvement: pathological findings at both biopsy and autopsy","volume":"31","author":"Suzuki","year":"2011","journal-title":"Neuropathology"},{"key":"10.1016\/j.trre.2024.100837_bb0410","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1111\/j.1399-3046.2012.01699.x","article-title":"Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation","volume":"16","author":"Twombley","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0415","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0425","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1523-1755.1998.00787.x","article-title":"Patient survival after renal transplantation: I. The impact of dialysis pre-transplant","volume":"53","author":"Cosio","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100837_bb0430","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/00007890-200211270-00005","article-title":"Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis","volume":"74","author":"Meier-Kriesche","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0435","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1523-1755.2000.00287.x","article-title":"Effect of waiting time on renal transplant outcome","volume":"58","author":"Meier-Kriesche","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100837_bb0440","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2019-125601","article-title":"Clinical features of post-transplant lymphoproliferative disease are different between kidney-transplant recipients from a cadaveric donor and those from a living donor","volume":"134","author":"Oshima","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100837_bb0445","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4103\/1319-2442.118069","article-title":"Characteristics and prognosis of lymphoproliferative disorders post-renal transplantation in living versus deceased donor allograft recipients","volume":"24","author":"Khedmat","year":"2013","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.trre.2024.100837_bb0450","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11255-008-9377-0","article-title":"Lymphoma after living donor kidney transplantation: an Iranian multicenter experience","volume":"40","author":"Pourfarziani","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.trre.2024.100837_bb0455","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1600-0560.2009.01449.x","article-title":"Cutaneous presentation of post-renal transplant lymphoproliferative disorder: a series of four cases","volume":"37","author":"Salama","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.trre.2024.100837_bb0460","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.transproceed.2005.12.093","article-title":"Posttransplant lymphoproliferative disorders in transplant recipients","volume":"38","author":"Timura\u01e7ao\u01e7lu","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100837_bb0465","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/107424840601100107","article-title":"Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience","volume":"11","author":"Wasson","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.trre.2024.100837_bb0470","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1442-2042.2009.02405.x","article-title":"Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years","volume":"17","author":"Abe","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.trre.2024.100837_bb0475","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00007890-199307000-00016","article-title":"Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center","volume":"56","author":"Cockfield","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0480","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1034\/j.1399-0012.2003.00054.x","article-title":"Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder","volume":"17","author":"Ganne","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0485","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1399-0012.2005.00406.x","article-title":"Post-transplant lymphoproliferative disorders after live donor renal transplantation","volume":"19","author":"Jain","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0490","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2000.18.21.3622","article-title":"Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center","volume":"18","author":"Mamzer-Bruneel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100837_bb0495","first-page":"4253","article-title":"Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus","volume":"41","author":"Hanto","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.trre.2024.100837_bb0500","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1001\/jama.294.21.2726","article-title":"Deceased-donor characteristics and the survival benefit of kidney transplantation","volume":"294","author":"Merion","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2024.100837_bb0505","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1681\/ASN.V1271538","article-title":"Increased immunogenicity and cause of graft loss of old donor kidneys","volume":"12","author":"De Fijter","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100837_bb0510","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/00007890-200211150-00014","article-title":"Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors","volume":"74","author":"Port","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0515","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2008.06.005","article-title":"A systematic review of kidney transplantation from expanded criteria donors","volume":"52","author":"Pascual","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100837_bb0520","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/tri.12736","article-title":"Comparison of survival outcomes between Expanded Criteria Donor and Standard Criteria Donor kidney transplant recipients: a systematic review and meta-analysis","volume":"29","author":"Querard","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100837_bb0525","first-page":"18","article-title":"Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study","volume":"351","author":"Aubert","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100837_bb0530","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5500\/wjt.v6.i1.103","article-title":"Renal transplantation with expanded criteria donors: which is the optimal immunosuppression?","volume":"6","author":"Filiopoulos","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0535","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jamainternmed.2019.2322","article-title":"Disparities in acceptance of deceased donor kidneys between the United States and France and estimated effects of increased US acceptance","volume":"179","author":"Aubert","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.trre.2024.100837_bb0540","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/ajt.14538","article-title":"Is the kidney donor profile index (KDPI) universal or UNOS-specific?","volume":"18","author":"Ekser","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100837_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-47772-7","article-title":"Validation of the Kidney Donor Profile Index (KDPI) to assess a deceased donor's kidneys' outcome in a European cohort","volume":"9","author":"Dahmen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.trre.2024.100837_bb0550","author":"Interim Report on Kidney Transplantation 2021\/2022"},{"key":"10.1016\/j.trre.2024.100837_bb0555","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/TP.0b013e31823f14d4","article-title":"A simplified donor risk index for predicting outcome after deceased donor kidney transplantation","volume":"93","author":"Watson","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0560","author":"Annual Report on Kidney Transplantation 2019\/20"},{"key":"10.1016\/j.trre.2024.100837_bb0565","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/TP.0000000000000375","article-title":"The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis","volume":"98","author":"Ma","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100837_bb0570","article-title":"Impact of donor age on clinical outcomes of primary single kidney transplantation from Maastricht category-III donors after circulatory death","volume":"4","author":"Favi","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2024.100837_bb0575","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ajt.13886","article-title":"Efficacy and safety outcomes of extended criteria donor kidneys by subtype: subgroup analysis of BENEFIT-EXT at 7 years after transplant","volume":"17","author":"Florman","year":"2017","journal-title":"Am J Transplant"}],"updated-by":[{"DOI":"10.1016\/j.trre.2024.100843","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X2400020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X2400020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:08:35Z","timestamp":1760630915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X2400020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0955470X2400020X"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2024.100837","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.trre.2024.100843","asserted-by":"object"}]},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2024.100837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100837"}}